"These results provide important clinical validation of our internal research demonstrating enhanced sensitivity of Merlin-negative mesothelioma to FAK inhibitors" Data presented by Verastem in breast cancer models lacking the tumor suppressor Merlin demonstrate that FAK inhibition effectively reduces cancer stem cells in vitro and in vivo.
http://eon.businesswire.com/news/eon/20121109005495/en/Verastem-Reports-Data-Focal-Adhesion-Kinase-Program
http://eon.businesswire.com/news/eon/20121109005495/en/Verastem-Reports-Data-Focal-Adhesion-Kinase-Program
No comments:
Post a Comment